Attovia Therapeutics, Inc. (ATTO)
| Market Cap | 673.85M-28.5% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 43.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,173.052 |
| Open | 16.27 |
| Previous Close | 16.42 |
| Day's Range | 15.47 - 16.38 |
| 52-Week Range | 15.47 - 28.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 45.33(+189.46%) |
| Earnings Date | n/a |
Attovia Therapeutics, Inc. has a live Insider Score.
Scored on 4 qualifying trades from 1 insider in the last 90 days.
About ATTO
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ATTO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATTO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATTO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATTO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ATTO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical, manufacturing, and preclinical services | $13.97M | 76.69% |
| Personnel-related costs | $2.92M | 16.04% |
| Professional consulting services | $889.00K | 4.88% |
| Facilities and overhead costs | $435.00K | 2.39% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ATTO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATTO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ATTO
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.58M |
| SCHASchwab U.S. Small-Cap ETF | $1.54M |
| VXFVanguard Extended Market ETF | $594.45K |
| VTWOVanguard Russell 2000 ETF | $380.96K |
| SCHBSchwab U.S. Broad Market ETF | $196.84K |
| VTWGVanguard Russell 2000 Growth ETF | $38.13K |
Estimated from each fund’s disclosed top holdings × AUM
ATTO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ATTO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score